Search

Your search keyword '"Jeger, Raban V"' showing total 279 results
Start Over Author "Jeger, Raban V"
279 results on '"Jeger, Raban V"'

2. Impact of the COVID-19 Pandemic on Global TAVR Activity: The COVID-TAVI Study

Author

Armario, Xavier, Carron, Jennifer, Simpkin, Andrew J., Elhadi, Mohamed, Kennedy, Ciara, Abdel-Wahab, Mohamed, Bleiziffer, Sabine, Lefèvre, Thierry, Wolf, Alexander, Pilgrim, Thomas, Villablanca, Pedro A., Blackman, Daniel J., Van Mieghem, Nicolas M., Hengstenberg, Christian, Swaans, Martin J., Prendergast, Bernard D., Patterson, Tiffany, Barbanti, Marco, Webb, John G., Behan, Miles, Resar, Jon, Chen, Mao, Hildick-Smith, David, Spence, Mark S., Zweiker, David, Bagur, Rodrigo, Teles, Rui, Ribichini, Flavio L., Jagielak, Dariusz, Park, Duk-Woo, Kornowski, Ran, Wykrzykowska, Joanna J., Bunc, Matjaz, Estévez-Loureiro, Rodrigo, Poon, Karl, Götberg, Matthias, Jeger, Raban V., Ince, Hüseyin, Packer, Erik J.S., Angelillis, Marco, Nombela-Franco, Luis, Guo, Yingqiang, Savontaus, Mikko, Al-Moghairi, Abdulrahman M., Parasca, Catalina Andreea, Kliger, Chad, Roy, David, Molnár, Levente, Silva, Mariana, White, Jonathon, Yamamoto, Masanori, Carrilho-Ferreira, Pedro, Toggweiler, Stefan, Voudris, Vassileios, Ohno, Yohei, Rodrigues, Inês, Parma, Radosław, Ojeda, Soledad, Toutouzas, Kostas, Regueiro, Ander, Grygier, Marek, AlMerri, Khaled, Cruz-González, Ignacio, Fridrich, Viliam, de la Torre Hernández, José M., Noble, Stephane, Kala, Petr, Asmarats, Lluis, Kurt, Ibrahim Halil, Bosmans, Johan, Erglis, Martins, Casserly, Ivan, Iskandarani, Dounia, Bhindi, Ravinay, Kefer, Joelle, Yin, Wei-Hsian, Rosseel, Liesbeth, Kim, Hyo-Soo, O'Connor, Stephen, Hellig, Farrel, Sztejfman, Matias, Mendiz, Oscar, Pineda, Andres M., Seth, Ashok, Pllaha, Elton, de Brito, Fabio S., Jr., Bajoras, Vilhelmas, Balghith, Mohammed A., Lee, Michael, Eid-Lidt, Guering, Vandeloo, Bert, Vaz, Vinicius Daher, Alasnag, Mirvat, Ussia, Gian Paolo, Tay, Edgar, Mayol, Jorge, Gunasekaran, Sengottuvelu, Sardella, Gennaro, Buddhari, Wacin, Kao, Hsien-Li, Dager, Antonio, Tzikas, Apostolos, Gudmundsdottir, Ingibjörg J., Edris, Ahmad, Gutiérrez Jaikel, Luis Abel, Arias, Eduardo A., Al-Hijji, Mohammed, Ertürk, Mehmet, Conde-Vela, César, Boljević, Darko, Ferrero Guadagnoli, Adolfo, Hermlin, Toomas, ElGuindy, Ahmed M., Lima-Filho, Moysés de Oliveira, de Moura Santos, Luciano, Perez, Luis, Maluenda, Gabriel, Akyüz, Ali Rıza, Alhaddad, Imad A., Amin, Haitham, So, Chak-Yu, Al Nooryani, Arif A., Vaca, Carlos, Albistur, Juan, Nguyen, Quang Ngoc, Arzamendi, Dabit, Grube, Eberhard, Modine, Thomas, Tchétché, Didier, Hayashida, Kentaro, Latib, Azeem, Makkar, Raj R., Piazza, Nicolo, Søndergaard, Lars, McEvoy, John William, and Mylotte, Darren

Published
2024
Full Text
View/download PDF

5. Transcatheter Aortic Valve Replacement With the LOTUS Edge System: Early European Experience

Author

Armario, Xavier, Rosseel, Liesbeth, Kharbanda, Rajesh, Khogali, Saib, Abdel-Wahab, Mohamed, Van Mieghem, Nicolas M., Tchétché, Didier, Dumonteil, Nicolas, De Backer, Ole, Cotton, James, McGrath, Brian, Balakrishnan, Deepu, Ali, Noman, Farhan, Serdar, Joseph, Jubin, Charbonnier, Gaetan, Okuno, Taishi, McHugh, Fiachra, Hildick-Smith, David, Gilgen, Nicole, Hokken, Thijmen, Spence, Mark S., Frerker, Christian, Angelillis, Marco, Grygier, Marek, Cockburn, James, Bjursten, Henrik, Jeger, Raban V., Teles, Rui, Petronio, Anna S., Pilgrim, Thomas, Sinning, Jan-Malte, Nickenig, Georg, Søndergaard, Lars, Blackman, Daniel J., and Mylotte, Darren

Published
2021
Full Text
View/download PDF

8. Association of chocolate consumption with neurological and cardiovascular outcomes in atrial fibrillation: data from two Swiss atrial fibrillation cohort studies (Swiss-AF and BEAT-AF)

Author

Stauber, Annina, primary, Müller, Andreas, additional, Rommers, Nikki, additional, Aeschbacher, Stefanie, additional, Rodondi, Nicolas, additional, Bonati, Leo H., additional, Beer, Juerg H., additional, Jeger, Raban V., additional, Kurz, David J., additional, Liedtke, Claudia, additional, Ammann, Peter, additional, Di Valentino, Marcello, additional, Chocano, Patricia, additional, Kobza, Richard, additional, Kühne, Michael, additional, Conen, David, additional, Osswald, Stefan, additional, and Bernheim, Alain M., additional

Published
2023
Full Text
View/download PDF

9. Impact of chronic kidney disease and diabetes on clinical outcomes in women undergoing PCI

Author

Spirito, Alessandro, primary, Itchhaporia, Dipti, additional, Sartori, Samantha, additional, Camenzind, Edoardo, additional, Chieffo, Alaide, additional, Dangas, George D., additional, Galatius, Soren, additional, Jeger, Raban V., additional, Kandzari, David E., additional, Kastrati, Adnan, additional, Kim, Hyo-Soo, additional, Kimura, Takeshi, additional, Leon, Martin B., additional, Mehta, Laxmi S., additional, Mikhail, Ghada W., additional, Morice, Marie-Claude, additional, Nicolas, Johny, additional, Pileggi, Brunna, additional, Serruys, Patrick W., additional, Smits, Pieter C., additional, Steg, P. Gabriel, additional, Stone, Gregg W., additional, Valgimigli, Marco, additional, Vogel, Birgit, additional, von Birgelen, Clemens, additional, Weisz, Giora, additional, Wijns, William, additional, Windecker, Stephan, additional, and Mehran, Roxana, additional

Published
2023
Full Text
View/download PDF

10. Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative

Author

Chandrasekhar, Jaya, Baber, Usman, Sartori, Samantha, Stefanini, Giulio G., Sarin, Michele, Vogel, Birgit, Farhan, Serdar, Camenzind, Edoardo, Leon, Martin B., Stone, Gregg W., Serruys, Patrick W., Wijns, William, Steg, Philippe G., Weisz, Giora, Chieffo, Alaide, Kastrati, Adnan, Windecker, Stephan, Morice, Marie-Claude, Smits, Pieter C., von Birgelen, Clemens, Mikhail, Ghada W., Itchhaporia, Dipti, Mehta, Laxmi, Kim, Hyo-Soo, Valgimigli, Marco, Jeger, Raban V., Kimura, Takeshi, Galatius, Søren, Kandzari, David, Dangas, George, and Mehran, Roxana

Published
2018
Full Text
View/download PDF

11. Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From a Patient-Level Pooled Analysis of Randomized Controlled Trials

Author

Faggioni, Michela, Baber, Usman, Afshar, Arash Ehteshami, Giustino, Gennaro, Sartori, Samantha, Sorrentino, Sabato, Steg, Philippe G., Stefanini, Giulio G., Windecker, Stephan, Leon, Martin B., Stone, Gregg W., Wijns, William, Serruys, Patrick W., Valgimigli, Marco, Camenzind, Edoardo, Weisz, Giora, Smits, Pieter C., Kandzari, David E., Galatius, Soren, Von Birgelen, Clemens, Jeger, Raban V., Mikhail, Ghada W., Itchhaporia, Dipti, Mehta, Laxmi, Ortega, Rebecca, Kim, Hyo-Soo, Kastrati, Adnan, Chieffo, Alaide, Dangas, George D., Morice, Marie-Claude, and Mehran, Roxana

Published
2018
Full Text
View/download PDF

12. Association of chocolate consumption with neurological and cardiovascular outcomes in atrial fibrillation: data from two Swiss atrial fibrillation cohort studies (Swiss-AF and BEAT-AF)

Author

Stauber, Annina; https://orcid.org/0009-0008-6006-8177, Müller, Andreas, Rommers, Nikki; https://orcid.org/0000-0003-0311-5009, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896, Bonati, Leo H; https://orcid.org/0000-0003-1163-8133, Beer, Juerg H, Jeger, Raban V; https://orcid.org/0000-0003-1290-5491, Kurz, David J; https://orcid.org/0000-0002-3921-6939, Liedtke, Claudia, Ammann, Peter, Di Valentino, Marcello; https://orcid.org/0000-0001-9088-6973, Chocano, Patricia, Kobza, Richard; https://orcid.org/0000-0003-3988-7262, Kühne, Michael; https://orcid.org/0000-0002-2937-3711, Conen, David; https://orcid.org/0000-0002-2459-5251, Osswald, Stefan; https://orcid.org/0000-0002-9240-6731, Bernheim, Alain M, Stauber, Annina; https://orcid.org/0009-0008-6006-8177, Müller, Andreas, Rommers, Nikki; https://orcid.org/0000-0003-0311-5009, Aeschbacher, Stefanie; https://orcid.org/0000-0001-8134-2421, Rodondi, Nicolas; https://orcid.org/0000-0001-9083-6896, Bonati, Leo H; https://orcid.org/0000-0003-1163-8133, Beer, Juerg H, Jeger, Raban V; https://orcid.org/0000-0003-1290-5491, Kurz, David J; https://orcid.org/0000-0002-3921-6939, Liedtke, Claudia, Ammann, Peter, Di Valentino, Marcello; https://orcid.org/0000-0001-9088-6973, Chocano, Patricia, Kobza, Richard; https://orcid.org/0000-0003-3988-7262, Kühne, Michael; https://orcid.org/0000-0002-2937-3711, Conen, David; https://orcid.org/0000-0002-2459-5251, Osswald, Stefan; https://orcid.org/0000-0002-9240-6731, and Bernheim, Alain M

Abstract

AIM: To assess the associations of chocolate consumption with neurocognitive function, brain lesions on magnetic resonance imaging (MRI), and cardiovascular outcome in patients with atrial fibrillation (AF). METHODS: We analysed data from patients of two prospective multicentre Swiss atrial fibrillation cohort studies (Swiss-AF) and (BEAT-AF). Assessments of MRI findings and neurocognitive function were performed only in the Swiss-AF population (in 1727 of 2415 patients [71.5%] with a complete data set), as patients enrolled in BEAT-AF were not systematically evaluated for these outcomes. Otherwise, the two cohorts had an equivalent set of clinical assessments. Clinical outcome analysis was performed in 3931 patients of both cohorts. Chocolate consumption was assessed by questionnaire. Patients were categorised as no/low chocolate consumption (No/Low-Ch) ≤1 servings/week, moderate chocolate consumption (Mod-Ch) >1–6 servings/week, and high chocolate consumption (High-Ch) >6 servings/week, respectively. Brain lesions were evaluated by MRI. Assessment of cognitive function was performed by neurocognitive functional testing and included global cognition measurement with a cognitive construct score. Cerebral MRI and cognition were evaluated at baseline. Cross-sectional associations between chocolate consumption and MRI findings were analysed by multivariate logistic regression models and associations with neurocognitive function by multivariate linear regression models. Clinical outcome events during follow-up were recorded and assessed by a clinical event committee. The associations between chocolate consumption and clinical outcomes were evaluated by Cox regression models. The median follow-up time was 6 years. RESULTS: Chocolate consumption was not associated with prevalence or volume of vascular brain lesions on MRI, nor major adverse cardiac events (ischaemic stroke, myocardial infarction, cardiovascular death). However, No/Low-Ch was independently associated with

Published
2023

15. Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration

Author

Giustino, Gennaro, Mastoris, Ioannis, Baber, Usman, Sartori, Samantha, Stone, Gregg W., Leon, Martin B., Serruys, Patrick W., Kastrati, Adnan, Windecker, Stephan, Valgimigli, Marco, Dangas, George D., Von Birgelen, Clemens, Smits, Pieter C., Kandzari, David, Galatius, Soren, Wijns, William, Steg, P. Gabriel, Stefanini, Giulio G., Aquino, Melissa, Morice, Marie-Claude, Camenzind, Edoardo, Weisz, Giora, Jeger, Raban V., Kimura, Takeshi, Mikhail, Ghada W., Itchhaporia, Dipti, Mehta, Laxmi, Ortega, Rebecca, Kim, Hyo-Soo, Chieffo, Alaide, and Mehran, Roxana

Published
2016
Full Text
View/download PDF

16. Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis

Author

Giustino, Gennaro, Baber, Usman, Aquino, Melissa, Sartori, Samantha, Stone, Gregg W., Leon, Martin B., Genereux, Philippe, Dangas, George D., Chandrasekhar, Jaya, Kimura, Takeshi, Salianski, Olga, Stefanini, Giulio G., Steg, P. Gabriel, Windecker, Stephan, Wijns, William, Serruys, Patrick W., Valgimigli, Marco, Morice, Marie-Claude, Camenzind, Edoardo, Weisz, Giora, Smits, Pieter C., Kandzari, David E., Galatius, Soren, Von Birgelen, Clemens, Saporito, Robert, Jeger, Raban V., Mikhail, Ghada W., Itchhaporia, Dipti, Mehta, Laxmi, Ortega, Rebecca, Kim, Hyo-Soo, Kastrati, Adnan, Chieffo, Alaide, and Mehran, Roxana

Published
2016
Full Text
View/download PDF

17. Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials

Author

Baber, Usman, Giustino, Gennaro, Sartori, Samantha, Aquino, Melissa, Stefanini, Giulio G., Steg, P. Gabriel, Windecker, Stephan, Leon, Martin B., Wijns, William, Serruys, Patrick W., Valgimigli, Marco, Stone, Gregg W., Dangas, George D., Morice, Marie-Claude, Camenzind, Edoardo, Weisz, Giora, Smits, Pieter C., Kandzari, David, Von Birgelen, Clemens, Mastoris, Ioannis, Galatius, Soren, Jeger, Raban V., Kimura, Takeshi, Mikhail, Ghada W., Itchhaporia, Dipti, Mehta, Laxmi, Ortega, Rebecca, Kim, Hyo-Soo, Kastrati, Adnan, Chieffo, Alaide, and Mehran, Roxana

Published
2016
Full Text
View/download PDF

18. Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents Collaborative Patient-Level Pooled Analysis

Author

Baber, Usman, Stefanini, Giulio G., Giustino, Gennaro, Stone, Gregg W., Leon, Martin B., Sartori, Samantha, Aquino, Melissa, Steg, P. Gabriel, Windecker, Stephan, Wijns, William, Serruys, Patrick W., Valgimigli, Marco, Morice, Marie–Claude, Camenzind, Edoardo, Weisz, Giora, Smits, Pieter C., Kandzari, David E., von Birgelen, Clemens, Dangas, George D., Galatius, Soren, Jeger, Raban V., Kimura, Takeshi, Mikhail, Ghada W., Itchhaporia, Dipti, Mehta, Laxmi, Ortega, Rebecca, Kim, Hyo-Soo, Kastrati, Adnan, Chieffo, Alaide, and Mehran, Roxana

Published
2019
Full Text
View/download PDF

19. Update valvuläre Herzkrankheiten: Entscheidungen im interdisziplinären Herzteam anhand von Beispielen.

Author

Bernheim, Alain M., Jeger, Raban V., Dzemali, Omer, and Papadopoulos, Nestoras

Subjects
*MEDICAL personnel, *AORTIC stenosis, *OLDER people, *POPULATION aging, *QUALITY of life
Abstract

In Europe, mitral regurgitation and aortic stenosis are the most common valve lesions requiring interventions. In advanced stages, these valve pathologies affect patients' quality of life and prognosis. The prevalence of mitral regurgitation and aortic stenosis is increasing with age. In view of an aging population and the comorbidities associated with age, these valve defects represent an increasing challenge to health care providers. Nowadays, surgical as well as catheter-based treatment options are available to treat affected patients. Therapeutic strategies suitable to the individual patient should be discussed in interdisciplinary heart teams. The aim of the present article is to give an overview of possible guideline-conform heart team decisions based on patient examples. [ABSTRACT FROM AUTHOR]

Published
2023

20. Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non–ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents

Author

Giustino, Gennaro, Baber, Usman, Stefanini, Giulio Giuseppe, Aquino, Melissa, Stone, Gregg W., Sartori, Samantha, Steg, Philippe Gabriel, Wijns, William, Smits, Pieter C., Jeger, Raban V., Leon, Martin B., Windecker, Stephan, Serruys, Patrick W., Morice, Marie-Claude, Camenzind, Edoardo, Weisz, Giora, Kandzari, David, Dangas, George D., Mastoris, Ioannis, Von Birgelen, Clemens, Galatius, Soren, Kimura, Takeshi, Mikhail, Ghada, Itchhaporia, Dipti, Mehta, Laxmi, Ortega, Rebecca, Kim, Hyo-Soo, Valgimigli, Marco, Kastrati, Adnan, Chieffo, Alaide, and Mehran, Roxana

Published
2015
Full Text
View/download PDF

21. Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial

Author

Scheller, Bruno, Rissanen, Tuomas T., Farah, Ahmed, Ohlow, Marc-Alexander, Mangner, Norman, Wöhrle, Jochen, Möbius-Winkler, Sven, Weilenmann, Daniel, Leibundgut, Gregor, Cuculi, Florim, Gilgen, Nicole, Coslovsky, Michael, Mahfoud, Felix, and Jeger, Raban V.

Subjects
coronary vessels, percutaneous coronary intervention, drug-eluting stents, population, mortality
Published
2022
Full Text
View/download PDF

22. Value of Periprocedural Electrophysiology Testing During Transcatheter Aortic Valve Replacement for Risk Stratification of Patients With New‐Onset Left Bundle‐Branch Block

Author

Badertscher, Patrick, primary, Knecht, Sven, additional, Spies, Florian, additional, Auberson, Chloé, additional, Salis, Marc, additional, Jeger, Raban V., additional, Fahrni, Gregor, additional, Kaiser, Christoph, additional, Schaer, Beat, additional, Osswald, Stefan, additional, Sticherling, Christian, additional, and Kühne, Michael, additional

Published
2022
Full Text
View/download PDF

24. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials

Author

Stefanini, Giulio G, Baber, Usman, Windecker, Stephan, Morice, Marie-Claude, Sartori, Samantha, Leon, Martin B, Stone, Gregg W, Serruys, Patrick W, Wijns, William, Weisz, Giora, Camenzind, Edoardo, Steg, Philippe G, Smits, Pieter C, Kandzari, David, Von Birgelen, Clemens, Galatius, Søren, Jeger, Raban V, Kimura, Takeshi, Mikhail, Ghada W, Itchhaporia, Dipti, Mehta, Laxmi, Ortega, Rebecca, Kim, Hyo-Soo, Valgimigli, Marco, Kastrati, Adnan, Chieffo, Alaide, and Mehran, Roxana

Published
2013
Full Text
View/download PDF

26. IMPACT OF CORONARY ARTERY DISEASE ON CLINICAL OUTCOMES AFTER TAVR: INSIGHTS FROM THE BRAVO-3 RANDOMIZED TRIAL

Author

Feldman, Daniel, primary, Cao, Davide, additional, Nicolas, Johny, additional, Hengstenberg, Christian, additional, Zhang, Zhongie, additional, Sartori, Samantha, additional, Beerkens, Frans, additional, Pivato, Carlo Andrea, additional, Chiarito, Mauro, additional, Satish, Mohan, additional, Jones, Davis B., additional, Iyer, Divya, additional, Power, David, additional, Chen, Huazhen, additional, Camaj, Anton, additional, Razuk, Victor, additional, Roumeliotis, Anastasios, additional, Jeger, Raban V., additional, Violini, Roberto, additional, Ferrari, Markus, additional, Mehran, Roxana, additional, and Dangas, George D., additional

Published
2022
Full Text
View/download PDF

27. IMPACT OF CHRONIC THROMBOCYTOPENIA ON CLINICAL OUTCOMES AFTER TAVR: INSIGHTS FROM THE BRAVO-3 RANDOMIZED TRIAL

Author

Feldman, Daniel, primary, Cao, Davide, additional, Razuk, Victor, additional, Nicolas, Johny, additional, Hengstenberg, Christian, additional, Zhang, Zhongie, additional, Sartori, Samantha, additional, Beerkens, Frans, additional, Pivato, Carlo Andrea, additional, Chiarito, Mauro, additional, Jones, Davis B., additional, Satish, Mohan, additional, Roumeliotis, Anastasios, additional, Power, David, additional, Camaj, Anton, additional, Jeger, Raban V., additional, Violini, Roberto, additional, Ferrari, Markus, additional, Mehran, Roxana, additional, and Dangas, George D., additional

Published
2022
Full Text
View/download PDF

28. Impact of Diabetes on Outcome With Drug-Coated Balloons Versus Drug-Eluting Stents

Author

Wöhrle, Jochen, primary, Scheller, Bruno, additional, Seeger, Julia, additional, Farah, Ahmed, additional, Ohlow, Marc-Alexander, additional, Mangner, Norman, additional, Möbius-Winkler, Sven, additional, Weilenmann, Daniel, additional, Stachel, Georg, additional, Leibundgut, Gregor, additional, Rickenbacher, Peter, additional, Cattaneo, Marco, additional, Gilgen, Nicole, additional, Kaiser, Christoph, additional, and Jeger, Raban V., additional

Published
2021
Full Text
View/download PDF

29. Transcatheter Aortic Valve Replacement With the LOTUS Edge System:Early European Experience

Author

Armario, Xavier, Rosseel, Liesbeth, Kharbanda, Rajesh, Khogali, Saib, Abdel-Wahab, Mohamed, Van Mieghem, Nicolas M., Tchétché, Didier, Dumonteil, Nicolas, De Backer, Ole, Cotton, James, McGrath, Brian, Balakrishnan, Deepu, Ali, Noman, Farhan, Serdar, Joseph, Jubin, Charbonnier, Gaetan, Okuno, Taishi, McHugh, Fiachra, Hildick-Smith, David, Gilgen, Nicole, Hokken, Thijmen, Spence, Mark S., Frerker, Christian, Angelillis, Marco, Grygier, Marek, Cockburn, James, Bjursten, Henrik, Jeger, Raban V., Teles, Rui, Petronio, Anna S., Pilgrim, Thomas, Sinning, Jan Malte, Nickenig, Georg, Søndergaard, Lars, Blackman, Daniel J., Mylotte, Darren, Armario, Xavier, Rosseel, Liesbeth, Kharbanda, Rajesh, Khogali, Saib, Abdel-Wahab, Mohamed, Van Mieghem, Nicolas M., Tchétché, Didier, Dumonteil, Nicolas, De Backer, Ole, Cotton, James, McGrath, Brian, Balakrishnan, Deepu, Ali, Noman, Farhan, Serdar, Joseph, Jubin, Charbonnier, Gaetan, Okuno, Taishi, McHugh, Fiachra, Hildick-Smith, David, Gilgen, Nicole, Hokken, Thijmen, Spence, Mark S., Frerker, Christian, Angelillis, Marco, Grygier, Marek, Cockburn, James, Bjursten, Henrik, Jeger, Raban V., Teles, Rui, Petronio, Anna S., Pilgrim, Thomas, Sinning, Jan Malte, Nickenig, Georg, Søndergaard, Lars, Blackman, Daniel J., and Mylotte, Darren

Abstract

Objectives: The aim of this study was to evaluate the short-term safety and efficacy of transcatheter aortic valve replacement (TAVR) with the LOTUS Edge system. Background: The LOTUS Edge system was commercially re-released in April 2019. The authors report the first European experience with this device. Methods: A multicenter, single-arm, retrospective registry was initiated to evaluate short-term clinical outcomes. Included cases are the first experience with this device and new implantation technique in Europe. Clinical, echocardiographic, and computed tomographic data were analyzed. Endpoints were defined according to Valve Academic Research Consortium-2 and were site reported. Results: Between April and November 2019, 286 consecutive patients undergoing TAVR with the LOTUS Edge system at 18 European centers were included. The mean age and Society of Thoracic Surgeons score were 81.2 ± 6.9 years and 5.2 ± 5.4%, respectively. Nearly one-half of all patients (47.9%) were considered to have complex anatomy. Thirty-day major adverse events included death (2.4% [n = 7]) and stroke (3.5% [n = 10]). After TAVR, the mean aortic valve area was 1.9 ± 0.9 cm2, and the mean transvalvular gradient was 11.9 ± 5.7 mm Hg. None or trace paravalvular leak (PVL) occurred in 84.4% and moderate PVL in 2.0%. There were no cases of severe PVL. New permanent pacemaker (PPM) implantation was required in 25.9% among all patients and 30.8% among PPM-naive patients. Conclusions: Early experience with the LOTUS Edge system demonstrated satisfactory short-term safety and efficacy, favorable hemodynamic data, and very low rates of PVL in an anatomically complex cohort. New PPM implantation remained high. Further study will evaluate if increasing operator experience with the device and new implantation technique can reduce the incidence of PPM implantation.

Published
2021

32. Long-Term Results After Drug-Eluting Versus Bare-Metal Stent Implantation in Saphenous Vein Grafts:Randomized Controlled Trial

Author

Fahrni, Gregor, Farah, Ahmed, Engstrøm, Thomas, Galatius, Søren, Eberli, Franz, Rickenbacher, Peter, Conen, David, Mueller, Christian, Pfister, Otmar, Twerenbold, Raphael, Coslovsky, Michael, Cattaneo, Marco, Kaiser, Christoph, Mangner, Norman, Schuler, Gerhard, Pfisterer, Matthias, Möbius-Winkler, Sven, Jeger, Raban V, Fahrni, Gregor, Farah, Ahmed, Engstrøm, Thomas, Galatius, Søren, Eberli, Franz, Rickenbacher, Peter, Conen, David, Mueller, Christian, Pfister, Otmar, Twerenbold, Raphael, Coslovsky, Michael, Cattaneo, Marco, Kaiser, Christoph, Mangner, Norman, Schuler, Gerhard, Pfisterer, Matthias, Möbius-Winkler, Sven, and Jeger, Raban V

Abstract

Background Efficacy data on drug-eluting stents (DES) versus bare-metal stents (BMS) in saphenous vein grafts are controversial. We aimed to compare DES with BMS among patients undergoing saphenous vein grafts intervention regarding long-term outcome. Methods and Results In this multinational trial, patients were randomized to paclitaxel-eluting or BMS. The primary end point was major adverse cardiac events (cardiac death, nonfatal myocardial infarction, and target-vessel revascularization at 1 year. Secondary end points included major adverse cardiac events and its individual components at 5-year follow-up. One hundred seventy-three patients were included in the trial (89 DES versus 84 BMS). One-year major adverse cardiac event rates were lower in DES compared with BMS (2.2% versus 16.0%, hazard ratio, 0.14; 95% CI, 0.03-0.64, P=0.01), which was mainly driven by a reduction of subsequent myocardial infarctions and need for target-vessel revascularization. Five-year major adverse cardiac event rates remained lower in the DES compared with the BMS arm (35.5% versus 56.1%, hazard ratio, 0.40; 95% CI, 0.23-0.68, P<0.001). A landmark-analysis from 1 to 5 years revealed a persistent benefit of DES over BMS (hazard ratio, 0.33; 95% CI, 0.13-0.74, P=0.007) in terms of target-vessel revascularization. More patients in the BMS group underwent multiple target-vessel revascularization procedures throughout the study period compared with the DES group (DES 1.1% [n=1] versus BMS 9.5% [n=8], P=0.013). Enrollment was stopped before the target sample size of 240 patients was reached. Conclusions In this randomized controlled trial with prospective long-term follow-up of up to 5 years, DES showed a better efficacy than BMS with sustained benefits over time. DES may be the preferred strategy in this patient population. Registration URL: https://www.clini​caltr​ials.gov; Unique identifier: NCT00595647.

Published
2020

33. Reduced leaflet motion after transcatheter aortic-valve replacement

Author

de Backer, Ole, Dangas, George D., Jilaihawi, Hasan, Leipsic, Jonathon A., Terkelsen, Christian J., Makkar, Raj, Kini, Annapoorna S., Veien, Karsten T., Abdel-Wahab, Mohamed, Kim, Won Keun, Balan, Prakash, van Mieghem, Nicolas, Mathiassen, Ole N., Jeger, Raban V., Arnold, Martin, Mehran, Roxana, Guimarães, Ana H.C., Nørgaard, Bjarne L., Kofoed, Klaus F., Blanke, Philipp, Windecker, Stephan, Søndergaard, Lars, de Backer, Ole, Dangas, George D., Jilaihawi, Hasan, Leipsic, Jonathon A., Terkelsen, Christian J., Makkar, Raj, Kini, Annapoorna S., Veien, Karsten T., Abdel-Wahab, Mohamed, Kim, Won Keun, Balan, Prakash, van Mieghem, Nicolas, Mathiassen, Ole N., Jeger, Raban V., Arnold, Martin, Mehran, Roxana, Guimarães, Ana H.C., Nørgaard, Bjarne L., Kofoed, Klaus F., Blanke, Philipp, Windecker, Stephan, and Søndergaard, Lars

Abstract

BACKGROUND Subclinical leaflet thickening and reduced leaflet motion of bioprosthetic aortic valves have been documented by four-dimensional computed tomography (CT). Whether anticoagulation can reduce these phenomena after transcatheter aortic-valve replacement (TAVR) is not known. METHODS In a substudy of a large randomized trial, we randomly assigned patients who had undergone successful TAVR and who did not have an indication for long-term anticoagulation to a rivaroxaban-based antithrombotic strategy (rivaroxaban [10 mg] plus aspirin [75 to 100 mg] once daily) or an antiplatelet-based strategy (clopidogrel [75 mg] plus aspirin [75 to 100 mg] once daily). Patients underwent evaluation by four-dimensional CT at a mean (±SD) of 90±15 days after randomization. The primary end point was the percentage of patients with at least one prosthetic valve leaflet with grade 3 or higher motion reduction (i.e., involving >50% of the leaflet). Leaflet thickening was also assessed. RESULTS A total of 231 patients were enrolled. At least one prosthetic valve leaflet with grade 3 or higher motion reduction was found in 2 of 97 patients (2.1%) who had scans that could be evaluated in the rivaroxaban group, as compared with 11 of 101 (10.9%) in the antiplatelet group (difference, -8.8 percentage points; 95% confidence interval [CI], -16.5 to -1.9; P=0.01). Thickening of at least one leaflet was observed in 12 of 97 patients (12.4%) in the rivaroxaban group and in 33 of 102 (32.4%) in the antiplatelet group (difference, -20.0 percentage points; 95% CI, -30.9 to -8.5). In the main trial, the risk of death or thromboembolic events and the risk of life-threatening, disabling, or major bleeding were higher with rivaroxaban (hazard ratios of 1.35 and 1.50, respectively). CONCLUSIONS In a substudy of a trial involving patients without an indication for long-term anticoagulation who had undergone successful TAVR, a rivaroxaban-based antithrombotic strategy was more effective than an

Published
2020

34. Interhospital transfer for early revascularization in patients with ST-elevation myocardial infarction complicated by cardiogenic shock -- a report from the SHould we revascularize Occluded Coronaries for cardiogenic shocK? (SHOCK) trial and registry

Author

Jeger, Raban V., Tseng, Chi-Hong, Hochman, Judith S., and Bates, Eric R.

Subjects
Cardiogenic shock -- Care and treatment, Cardiac patients -- Care and treatment, Medical colleges, Clinical trials, Health
Abstract

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ahj.2006.06.010 Byline: Raban V. Jeger (a), Chi-Hong Tseng (b), Judith S. Hochman (a), Eric R. Bates (c) Abstract: Early revascularization (ERV) in patients with ST-elevation myocardial infarction (STEMI) and cardiogenic shock (CS) reduces mortality rates. Patients admitted to hospitals without revascularization capability have high mortality rates and are not often transferred for ERV. Author Affiliation: (a) Cardiovascular Clinical Research Center, New York University School of Medicine, New York, NY (b) Division of Biostatistics, New York University School of Medicine, New York, NY (c) Division of Cardiovascular Medicine, University of Michigan Medical Center, Ann Arbor, MI Article History: Received 10 March 2006; Accepted 21 June 2006

Published
2006

35. Long-term prognostic value of the preoperative 12-lead electrocardiogram before major noncardiac surgery in coronary artery disease

Author

Jeger, Raban V., Probst, Cecilia, Arsenic, Ruza, Lippuner, Thomas, Pfisterer, Matthias E., Seeberger, Manfred D., and Filipovic, Miodrag

Subjects
Coronary heart disease -- Care and treatment, Coronary heart disease -- Patient outcomes, Electrocardiogram -- Research, Electrocardiography -- Research, Preoperative care -- Research, Cardiac patients -- Prognosis, Heart -- Surgery, Heart -- Patient outcomes, Health
Published
2006

37. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial

Author

Jeger, Raban V, primary, Farah, Ahmed, additional, Ohlow, Marc-Alexander, additional, Mangner, Norman, additional, Möbius-Winkler, Sven, additional, Weilenmann, Daniel, additional, Wöhrle, Jochen, additional, Stachel, Georg, additional, Markovic, Sinisa, additional, Leibundgut, Gregor, additional, Rickenbacher, Peter, additional, Osswald, Stefan, additional, Cattaneo, Marco, additional, Gilgen, Nicole, additional, Kaiser, Christoph, additional, Scheller, Bruno, additional, Ammann, Peter, additional, Awad, Belal, additional, Baumgartner, Margarete, additional, Boehm, Michael, additional, Bohl, Steffen, additional, Bruch, Leonhard, additional, Buckert, Dominik, additional, Buser, Peter, additional, Butter, Christian, additional, Clever, Yvonne P., additional, Cremers, Bodo, additional, Cuculi, Florim, additional, Dannberg, Gudrun, additional, Erne, Paul, additional, Ewen, Sebastian, additional, Fahrni, Gregor, additional, Franz, Marcus, additional, Haager, Philipp, additional, Harder-Allgoewer, Andrea, additional, Hoffmann, Andreas, additional, Höllriegel, Robert, additional, Hölschermann, Frank, additional, Jerichow, Timo, additional, Joerg, Lucas, additional, Kapos, Ioannis, additional, Keweloh, Boris, additional, Kherad, Behrouz, additional, Kühne, Michael, additional, Lauer, Bernward, additional, Lenk, Karsten, additional, Lenz, Corinna, additional, Von Lewinski, Dirk, additional, Linke, Axel, additional, Luha, Olev, additional, Maeder, Micha, additional, Mahfoud, Felix, additional, Mueller, Christian, additional, Neuss, Michael, additional, Niederl, Ella, additional, Noutsias, Michel, additional, Nuessli, Dominique, additional, Oenal, Ismet, additional, Otto, Sylvia, additional, Paliskyte, Rima, additional, Perl, Sabine, additional, Pieske, Burkert, additional, Plicht, Bjoern, additional, Poerner, Tudor C, additional, Richter, Stefan, additional, Rickli, Hans, additional, Riede, Florian, additional, Roelli, Hans, additional, Roettgen, Alexandra, additional, Rohner, Franziska, additional, Schirmer, Stephan, additional, Schmidt, Albrecht, additional, Schreiber, Matthias, additional, Seidel, Mirko, additional, Stephan, Frank-Peter, additional, Sticherling, Christian, additional, Struck, Berthold, additional, Surber, Ralf, additional, Tambor, Grit, additional, Toggweiler, Stefan, additional, Trachsel, Lukas, additional, Twerenbold, Raphael, additional, Wagner, Andreas, additional, Wein, Bastian, additional, Winkler, Sebastian, additional, Winzer, Ephraim, additional, Wolf, Alexander, additional, Zellweger, Michael, additional, Krackhardt, Florian, additional, and Zweiker, Robert, additional

Published
2020
Full Text
View/download PDF

40. Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement

Author

De Backer, Ole, primary, Dangas, George D., additional, Jilaihawi, Hasan, additional, Leipsic, Jonathon A., additional, Terkelsen, Christian J., additional, Makkar, Raj, additional, Kini, Annapoorna S., additional, Veien, Karsten T., additional, Abdel-Wahab, Mohamed, additional, Kim, Won-Keun, additional, Balan, Prakash, additional, Van Mieghem, Nicolas, additional, Mathiassen, Ole N., additional, Jeger, Raban V., additional, Arnold, Martin, additional, Mehran, Roxana, additional, Guimarães, Ana H.C., additional, Nørgaard, Bjarne L., additional, Kofoed, Klaus F., additional, Blanke, Philipp, additional, Windecker, Stephan, additional, and Søndergaard, Lars, additional

Published
2020
Full Text
View/download PDF

48. Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II

Author

Ricottini, Elisabetta, Ricottini, E ( Elisabetta ), Jeger, Raban V; https://orcid.org/0000-0003-1290-5491, Pfisterer, Matthias, Vogt, Deborah R; https://orcid.org/0000-0002-0668-5675, Galatius, Søren, Abildgaard, Ulrik, Naber, Christoph, Alber, Hannes, Eberli, Franz, Kurz, David J; https://orcid.org/0000-0002-3921-6939, Pedrazzini, Giovanni, Vuilliomenet, André, Weilenmann, Daniel, Rickli, Hans, Hansen, Kim Wadt; https://orcid.org/0000-0003-0851-5095, Rickenbacher, Peter, Conen, David, Müller, Christian, Osswald, Stefan, Gilgen, Nicole, Kaiser, Christoph, Ricottini, Elisabetta, Ricottini, E ( Elisabetta ), Jeger, Raban V; https://orcid.org/0000-0003-1290-5491, Pfisterer, Matthias, Vogt, Deborah R; https://orcid.org/0000-0002-0668-5675, Galatius, Søren, Abildgaard, Ulrik, Naber, Christoph, Alber, Hannes, Eberli, Franz, Kurz, David J; https://orcid.org/0000-0002-3921-6939, Pedrazzini, Giovanni, Vuilliomenet, André, Weilenmann, Daniel, Rickli, Hans, Hansen, Kim Wadt; https://orcid.org/0000-0003-0851-5095, Rickenbacher, Peter, Conen, David, Müller, Christian, Osswald, Stefan, Gilgen, Nicole, and Kaiser, Christoph

Abstract

BACKGROUND: Dual antiplatelet therapy (DAPT) prevents thrombotic events after coronary stent implantation but may induce bleedings, specifically in elderly patients. However, a competitive risk analysis is lacking. OBJECTIVES: To assess the determinants of major bleeding and the balance between the competing risks of major bleeding and thrombotic events during prasugrel-based DAPT after stent implantation. METHODS: Overall, 2,291 patients randomized to drug-eluting or bare metal stents and treated with prasugrel 10mg/day for 1 year were followed over 2 years for major bleeding (BARC 3/5) and thrombotic events (cardiac death, myocardial infarction, definitive/probable stent thrombosis). Prasugrel dose was reduced to 5mg in patients >75 years and/or <60kg. Predictors of major bleeding and competing risks of major bleeding and thrombotic events were assessed. RESULTS: Two-year rates of major bleeding and thrombotic events were 2.9% and 9.0%, respectively. The only independent predictor of major bleeding was age (hazard ratio per year increase 1.05 [1.02,1.07], p<0.001). The relationship between major bleeding and age was non-linear, with lowest hazard ratios at 57 years and an exponential increase only above 65 years. In contrast, the relationship between thrombotic events and age was linear and continuously increasing with older age. While the competing risk of thrombotic events was higher than that of major bleeding in younger patients, the two risks were similar in older patients. After discontinuation of prasugrel, bleeding events leveled off in all patients, while thrombotic events continued to increase. CONCLUSIONS: In prasugrel-based DAPT, age is the strongest risk factor for major bleeding, increasing exponentially >65 years. In younger patients, thrombotic events represent a higher risk than bleeding, while thrombotic and bleeding risks were similar in older patients. Important clinical implications relate to prasugrel dose in the elderly, duration of DAPT and

Published
2019

50. Heart failure in patients admitted for acute coronary syndromes: A report from a large national registry

Author

Jeger, Raban V, Pfister, Otmar, Radovanovic, Dragana, Eberli, Franz R, Rickli, Hans, Urban, Philip, Pedrazzini, Giovanni, Stauffer, Jean-Christophe, Nossen, Jörg, Erne, Paul, AMIS Plus Investigators, University of Zurich, and Jeger, Raban V

Subjects
610 Medicine & health, 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI), General Medicine, Cardiology and Cardiovascular Medicine, 11171 Cardiocentro Ticino, 2705 Cardiology and Cardiovascular Medicine
Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results